Virus reactivation: A panoramic view in human infections

Future Virology

Volumn 6, Issue 4, 2011, Pages 451-463

  Traylen, Christopher M ^a   Patel, Hersh R ^a   Fondaw, Wylder ^a   Mahatme, Sheran ^a   Williams, John F ^a   Walker, Lia R ^a   Dyson, Ossie F ^a   Arce, Sergio ^a   Akula, Shaw M ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

Author keywords

adenoviridae; cellular factors; herpesviridae; latency; lytic; parvoviridae; polyomaviridae; reactivation

Indexed keywords

(1,3 BENZOTHIAZOL 2 YL)[2 [2 (3 PYRIDINYL)ETHYLAMINO] 4 PYRIMIDINYL]ACETONITRILE; BORTEZOMIB; CELL PROTEIN; CURCUMIN; DILMAPIMOD; E 6201; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; SELUMETINIB; UNCLASSIFIED DRUG; VEMURAFENIB; VIRUS PROTEIN; VX 702;

ADENOVIRUS; ADENOVIRUS INFECTION; BK VIRUS; CELL DAMAGE; CELL STIMULATION; CLINICAL TRIAL (TOPIC); CYTOMEGALOVIRUS INFECTION; DRUG MECHANISM; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; HERPES SIMPLEX; HERPES SIMPLEX VIRUS; HERPES VIRUS INFECTION; HERPES ZOSTER; HUMAN; HUMAN CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 6; HUMAN HERPESVIRUS 7; HUMAN HERPESVIRUS 8; JC VIRUS; LATENT VIRUS INFECTION; NONHUMAN; PARVOVIRUS; PARVOVIRUS INFECTION; PERSISTENT VIRUS INFECTION; POLYOMAVIRUS INFECTION; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; VARICELLA ZOSTER VIRUS; VIRUS CELL INTERACTION; VIRUS GENOME; VIRUS INFECTION; VIRUS PARTICLE; VIRUS REACTIVATION; VIRUS REPLICATION;

ADENOVIRIDAE; BK POLYOMAVIRUS; HERPESVIRIDAE; HUMAN HERPESVIRUS 3; HUMAN HERPESVIRUS 4; HUMAN HERPESVIRUS 5; HUMAN HERPESVIRUS 6; HUMAN HERPESVIRUS 7; HUMAN HERPESVIRUS 8; JC POLYOMAVIRUS; PARVOVIRIDAE; PARVOVIRUS; POLYOMAVIRIDAE; SIMPLEXVIRUS;

EID: 79955770846     PISSN: 17460794     EISSN: None     Source Type: Journal    
DOI: 10.2217/fvl.11.21     Document Type: Review

References (145)

1. Cook SD, Paveloff MJ, Doucet JJ, Cottingham AJ, Sedarati F, Hill JM: Ocular herpes simplex virus reactivation in mice latently infected with latency-associated transcript mutants. Invest. Ophthalmol. Vis. Sci. 32, 1558-1561 (1991).
2. Margolis TP, Elfman FL, Leib D et al.: Spontaneous reactivation of herpes simplex virus type 1 in latently infected murine sensory ganglia. J. Virol. 81, 11069-11074 (2007). (Pubitemid 47536079)
3. Renne R, Lagunoff M, Zhong W, Ganem D: The size and conformation of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) DNA in infected cells and virions. J. Virol. 70, 8151-8154 (1996). (Pubitemid 26339129)
4. Jordan A, Bisgrove D, Verdin E: HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. EMBO J. 22, 1868-1877 (2003). (Pubitemid 36460143)
5. Schroder AR, Shinn P, Chen H, Berry C, Ecker JR, Bushman F: HIV-1 integration in the human genome favors active genes and local hotspots. Cell 110, 521-529 (2002). (Pubitemid 35232295)
6. Finzi D, Blankson J, Siliciano JD et al.: Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat. Med. 5, 512-517 (1999). (Pubitemid 29220209)
7. Shuda M, Feng H, Kwun HJ et al.: T antigen mutations are a human tumor-specific signature for Merkel cell polyomavirus. Proc. Natl Acad. Sci. USA 105, 16272-16277 (2008).
8. Gjoerup O, Chang Y: Update on human polyomaviruses and cancer. Adv. Cancer Res. 106, 1-51 (2010).
9. Morissette G, Flamand L: Herpesviruses and chromosomal integration. J. Virol. 84, 12100-12109 (2010).
10. Clark DA, Nacheva EP, Leong HN et al.: Transmission of integrated human herpesvirus 6 through stem cell transplantation: implications for laboratory diagnosis. J. Infect. Dis. 193, 912-916 (2006).
11. Tal-Singer R, Lasner TM, Podrzucki W et al.: Gene expression during reactivation of herpes simplex virus type 1 from latency in the peripheral nervous system is different from that during lytic infection of tissue cultures. J. Virol. 71, 5268-5276 (1997). (Pubitemid 27258200)
12. Bloom DC, Giordani NV, Kwiatkowski DL: Epigenetic regulation of latent HSV-1 gene expression. Biochim. Biophys. Acta 1799, 246-256 (2010).
13. Mador N, Panet A, Steiner I: The latency-associated gene of herpes simplex virus type 1 (HSV-1) interferes with superinfection by HSV-1. J. Neurovirol. 8(Suppl. 2), 97-102 (2002). (Pubitemid 36097784)
14. Ahmed M, Lock M, Miller CG, Fraser NW: Regions of the herpes simplex virus type 1 latency-associated transcript that protect cells from apoptosis in vitro and protect neuronal cells in vivo. J. Virol. 76, 717-729 (2002). (Pubitemid 34033370)
15. Perng GC, Maguen B, Jin L et al.: A gene capable of blocking apoptosis can substitute for the herpes simplex virus type 1 latency-associated transcript gene and restore wild-type reactivation levels. J. Virol. 76, 1224-1235 (2002). (Pubitemid 34066426)
16. Devi-Rao GB, Bloom DC, Stevens JG, Wagner EK: Herpes simplex virus type 1 DNA replication and gene expression during explant-induced reactivation of latently infected murine sensory ganglia. J. Virol. 68, 1271-1282 (1994). (Pubitemid 24065688)
17. Garber DA, Schaffer PA, Knipe DM: A LAT-associated function reduces productive-cycle gene expression during acute infection of murine sensory neurons with herpes simplex virus type 1. J. Virol. 71, 5885-5893 (1997). (Pubitemid 27304925)
18. Jones C: Herpes simplex virus type 1 and bovine herpesvirus 1 latency. Clin. Microbiol. Rev. 16, 79-95 (2003). (Pubitemid 36114708)
19. Halford WP, Kemp CD, Isler JA, Davido DJ, Schaffer PA: ICP0, ICP4, or VP16 expressed from adenovirus vectors induces reactivation of latent herpes simplex virus type 1 in primary cultures of latently infected trigeminal ganglion cells. J. Virol. 75, 6143-6153 (2001). (Pubitemid 32553145)
20. Loiacono CM, Taus NS, Mitchell WJ: The herpes simplex virus type 1 ICP0 promoter is activated by viral reactivation stimuli in trigeminal ganglia neurons of transgenic mice. J. Neurovirol. 9, 336-345 (2003). (Pubitemid 36874709)
21. Thompson RL, Sawtell NM: Evidence that the herpes simplex virus type 1 ICP0 protein does not initiate reactivation from latency in vivo. J. Virol. 80, 10919-10930 (2006). (Pubitemid 44706533)
22. Miller CS, Danaher RJ, Jacob RJ: ICP0 is not required for efficient stress-induced reactivation of herpes simplex virus type 1 from cultured quiescently infected neuronal cells. J. Virol. 80, 3360-3368 (2006).
23. Zhu XX, Chen JX, Young CS, Silverstein S: Reactivation of latent herpes simplex virus by adenovirus recombinants encoding mutant IE-0 gene products. J. Virol. 64, 4489-4498 (1990). (Pubitemid 20279862)
24. Weaver BA: Herpes zoster overview: natural history and incidence. J. Am. Osteopath. Assoc. 109, S2-S6 (2009).
25. Donahue JG, Choo PW, Manson JE, Platt R: The incidence of herpes zoster. Arch. Intern. Med. 155, 1605-1609 (2009).
26. Gilden DH, Cohrs R, Mahalingam R: Clinical and molecular pathogenesis of varicella virus infection. Viral Immunol. 16, 243-258 (2003). (Pubitemid 37229539)
27. Gilden D, Nagel MA, Mahalingam R et al.: Clinical and molecular aspects of varicella zoster virus infection. Future Neurol. 4, 103-117 (2009).
28. Amon W, Farrell PJ: Reactivation of Epstein-Barr virus from latency. Rev. Med. Virol. 15, 149-156 (2005). (Pubitemid 40675906)
29. Young LS, Rickinson AB: Epstein-Barr virus: 40 years on. Nat. Rev. Cancer 4, 757-768 (2004). (Pubitemid 39331148)
30. Heather J, Flower K, Isaac S, Sinclair AJ: The Epstein-Barr virus lytic cycle activator Zta interacts with methylated ZRE in the promoter of host target gene egr1. J. Gen. Virol. 90, 1450-1454 (2009).
31. Hong GK, Gulley ML, Feng WH, Delecluse HJ, Holley-Guthrie E, Kenney SC: Epstein-Barr virus lytic infection contributes to lymphoproliferative disease in a SCID mouse model. J. Virol. 79, 13993-14003 (2005). (Pubitemid 41552698)
32. Mendelson M, Monard S, Sissons P, Sinclair J: Detection of endogenous human cytomegalovirus in CD34+ bone marrow progenitors. J. Gen. Virol. 77(Pt 12), 3099-3102 (1996). (Pubitemid 27056530)
33. Reeves MB, MacAry PA, Lehner PJ, Sissons JG, Sinclair JH: Latency, chromatin remodeling, and reactivation of human cytomegalovirus in the dendritic cells of healthy carriers. Proc. Natl Acad. Sci. USA 102, 4140-4145 (2005). (Pubitemid 40388569)
34. Sinclair J: Human cytomegalovirus: latency and reactivation in the myeloid lineage. J. Clin. Virol. 41, 180-185 (2008).
35. Chan YJ, Chiou CJ, Huang Q, Hayward GS: Synergistic interactions between overlapping binding sites for the serum response factor and ELK-1 proteins mediate both basal enhancement and phorbol ester responsiveness of primate cytomegalovirus major immediate-early promoters in monocyte and T-lymphocyte cell types. J. Virol. 70, 8590-8605 (1996). (Pubitemid 26378439)
36. Abdel Massih RC, Razonable RR: Human herpesvirus 6 infections after liver transplantation. World J. Gastroenterol. 15, 2561-2569 (2009).
37. Kondo K: Human herpesvirus latency and fatigue. Uirusu 55, 9-17 (2005).
38. Caselli E, Di Luca D: Molecular biology and clinical associations of Roseoloviruses human herpesvirus 6 and human herpesvirus 7. New Microbiol. 30, 173-187 (2007). (Pubitemid 47264876)
39. Papanikolaou E, Kouvatsis V, Dimitriadis G, Inoue N, Arsenakis M: Identification and characterization of the gene products of open reading frame U86/87 of human herpesvirus 6. Virus Res. 89, 89-101 (2002). (Pubitemid 35284060)
40. Lu C, Zeng Y, Huang Z et al.: Human herpesvirus 6 activates lytic cycle replication of Kaposi's sarcoma-associated herpesvirus. Am. J. Pathol. 166, 173-183 (2005). (Pubitemid 40051670)
41. Boutolleau D, Fernandez C, Andre E et al.: Human herpesvirus (HHV)-6 and HHV-7: two closely related viruses with different infection profiles in stem cell transplantation recipients. J. Infect. Dis. 187, 179-186 (2003). (Pubitemid 36132631)
42. Neipel F, Albrecht JC, Fleckenstein B: Human herpesvirus 8 - the first human Rhadinovirus. J. Natl Cancer Inst. Monogr. 23, 73-77 (1998).
43. Sun R, Lin SF, Gradoville L, Yuan Y, Zhu F, Miller G: A viral gene that activates lytic cycle expression of Kaposi's sarcoma-associated herpesvirus. Proc. Natl Acad. Sci. USA 95, 10866-10871 (1998).
44. Liao W, Tang Y, Lin SF, Kung HJ, Giam CZ: K-bZIP of Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 (KSHV/HHV-8) binds KSHV/HHV-8 Rta and represses Rta-mediated transactivation. J. Virol. 77, 3809-3815 (2003). (Pubitemid 36297299)
45. Bryan BA, Dyson OF, Akula SM: Identifying cellular genes crucial for the reactivation of Kaposi's sarcoma-associated herpesvirus latency. J. Gen. Virol. 87, 519-529 (2006).
46. Vieira J, O'Hearn P, Kimball L, Chandran B, Corey L: Activation of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) lytic replication by human cytomegalovirus. J. Virol. 75, 1378-1386 (2001). (Pubitemid 32094696)
47. Randhawa P, Zygmunt D, Shapiro R et al.: Viral regulatory region sequence variations in kidney tissue obtained from patients with BK virus nephropathy. Kidney Int. 64, 743-747 (2003). (Pubitemid 36871950)
48. Mishra L, Rose JA: Adeno-associated virus DNA replication is induced by genes that are essential for HSV-1 DNA synthesis. Virology 179, 632-639 (1990).
49. Hill JM, Lukiw WJ, Gebhardt BM et al.: Gene expression analyzed by microarrays in HSV-1 latent mouse trigeminal ganglion following heat stress. Virus Genes 23, 273-280 (2001). (Pubitemid 33131866)
50. Higaki S, Gebhardt BM, Lukiw WJ, Thompson HW, Hill JM: Effect of immunosuppression on gene expression in the HSV-1 latently infected mouse trigeminal ganglion. Invest. Ophthalmol. Vis. Sci. 43, 1862-1869 (2002). (Pubitemid 34587033)
51. Bouchard C, Thieke K, Maier A et al.: Direct induction of cyclin D2 by Myc contributes to cell cycle progression and sequestration of p27. EMBO J. 18, 5321-5333 (1999). (Pubitemid 29465582)
52. Padar A, Sathyanarayana UG, Suzuki M et al.: Inactivation of cyclin D2 gene in prostate cancers by aberrant promoter methylation. Clin. Cancer Res. 9, 4730-4734 (2003). (Pubitemid 37323275)
53. Naray-Fejes-Toth A, Fejes-Toth G, Volk KA, Stokes JB: SGK is a primary glucocorticoid-induced gene in the human. J. Steroid Biochem. Mol. Biol. 75, 51-56 (2000). (Pubitemid 32155423)
54. Schang LM, Rosenberg A, Schaffer PA: Transcription of herpes simplex virus immediate-early and early genes is inhibited by roscovitine, an inhibitor specific for cellular cyclin-dependent kinases. J. Virol. 73, 2161-2172 (1999). (Pubitemid 29098121)
55. Schang LM, Bantly A, Schaffer PA: Explant-induced reactivation of herpes simplex virus occurs in neurons expressing nuclear CDK2 and CDK4. J. Virol. 76, 7724-7735 (2002). (Pubitemid 34760996)
56. Camarena V, Kobayashi M, Kim JY et al.: Nature and duration of growth factor signaling through receptor tyrosine kinases regulates HSV-1 latency in neurons. Cell Host Microbe 8, 320-333 (2010).
57. Kalamvoki M, Roizman B: ICP0 enables and monitors the function of D cyclins in herpes simplex virus 1 infected cells. Proc. Natl Acad. Sci. USA 106, 14576-14580 (2009).
58. Rahaus M, Desloges N, Wolff MH: Varicella-zoster virus influences the activities of components and targets of the ERK signalling pathway. J. Gen. Virol. 87, 749-758 (2006).
59. Chang Y, Lee HH, Chen YT et al.: Induction of the early growth response 1 gene by Epstein-Barr virus lytic transactivator Zta. J. Virol. 80, 7748-7755 (2006). (Pubitemid 44092594)
60. Matusali G, Arena G, De Leo A, Di Renzo L, Mattia E: Inhibition of p38 MAP kinase pathway induces apoptosis and prevents Epstein Barr virus reactivation in Raji cells exposed to lytic cycle inducing compounds. Mol. Cancer 8, 18 (2009).
61. Eliopoulos AG, Caamano JH, Flavell J et al.: Epstein-Barr virus-encoded latent infection membrane protein 1 regulates the processing of p100 NF-kB2 to p52 via an IKKg/ NEMO-independent signalling pathway. Oncogene 22, 7557-7569 (2003). (Pubitemid 37464088)
62. Lee YH, Chiu YF, Wang WH, Chang LK, Liu ST: Activation of the ERK signal transduction pathway by Epstein-Barr virus immediate-early protein Rta. J. Gen. Virol. 89, 2437-2446 (2008).
63. Ho M: The history of cytomegalovirus and its diseases. Med. Microbiol. Immunol. 197, 65-73 (2008).
64. Lee Y, Sohn W J, Kim DS, Kwon HJ: NF-kB- and c-Jun-dependent regulation of human cytomegalovirus immediate-early gene enhancer/promoter in response to lipopolysaccharide and bacterial CpG-oligodeoxynucleotides in macrophage cell line RAW 264.7. Eur. J. Biochem. 271, 1094-1105 (2004). (Pubitemid 38373043)
65. Benedict CA, Angulo A, Patterson G et al.: Neutrality of the canonical NF-kB-dependent pathway for human and murine cytomegalovirus transcription and replication in vitro. J. Virol. 78, 741-750 (2004). (Pubitemid 38067596)
66. Hummel M, Abecassis MM: A model for reactivation of CMV from latency. J. Clin. Virol. 25(Suppl. 2), S123-S136 (2002). (Pubitemid 35287198)
67. Wright E, Bain M, Teague L, Murphy J, Sinclair J: Ets-2 repressor factor recruits histone deacetylase to silence human cytomegalovirus immediate-early gene expression in non-permissive cells. J. Gen. Virol. 86, 535-544 (2005). (Pubitemid 40331232)
68. Eberharter A, Becker PB: Histone acetylation: a switch between repressive and permissive chromatin. Second in review series on chromatin dynamics. EMBO Rep. 3, 224-229 (2002). (Pubitemid 34269514)
69. Kubat NJ, Tran RK, McAnany P, Bloom DC: Specific histone tail modification and not DNA methylation is a determinant of herpes simplex virus type 1 latent gene expression. J. Virol. 78, 1139-1149 (2004). (Pubitemid 38095824)
70. Mlechkovich G, Frenkel N: Human herpesvirus 6A (HHV-6A) and HHV-6B alter E2F1/Rb pathways and E2F1 localization and cause cell cycle arrest in infected T cells. J. Virol. 81, 13499-13508 (2007). (Pubitemid 350247844)
71. Vogelstein B, Lane D, Levine AJ: Surfing the p53 network. Nature 408, 307-310 (2000).
72. Oster B, Kofod-Olsen E, Bundgaard B, Hollsberg P: Restriction of human herpesvirus 6B replication by p53. J. Gen. Virol. 89, 1106-1113 (2008).
73. Black JB, Pellett PE: Human herpesvirus 7. Rev. Med. Virol. 9, 245-262 (1999).
74. Frenkel N, Wyatt LS: HHV-6 and HHV-7 as exogenous agents in human lymphocytes. Dev. Biol. Stand. 76, 259-265 (1992).
75. Katsafanas GC, Schirmer EC, Wyatt LS, Frenkel N: In vitro activation of human herpesviruses 6 and 7 from latency. Proc. Natl Acad. Sci. USA 93, 9788-9792 (1996). (Pubitemid 26296687)
76. McAllister SC, Hansen SG, Messaoudi I, Nikolich-Zugich J, Moses AV: Increased efficiency of phorbol ester-induced lytic reactivation of Kaposi's sarcoma-associated herpesvirus during S phase. J. Virol. 79, 2626-2630 (2005). (Pubitemid 40204617)
77. Cohen A, Brodie C, Sarid R: An essential role of ERK signalling in TPA-induced reactivation of Kaposi's sarcoma-associated herpesvirus. J. Gen. Virol. 87, 795-802 (2006).
78. Ford PW, Bryan BA, Dyson OF, Weidner DA, Chintalgattu V, Akula SM: Raf/MEK/ERK signalling triggers reactivation of Kaposi's sarcoma-associated herpesvirus latency. J. Gen. Virol. 87, 1139-1144 (2006).
79. Yu F, Harada JN, Brown H et al.: Systematic identification of cellular signals reactivating Kaposi sarcoma-associated herpesvirus. PLoS Pathog. 3, E44 (2007).
80. Xie J, Ajibade AO, Ye F, Kuhne K, Gao SJ: Reactivation of Kaposi's sarcoma-associated herpesvirus from latency requires MEK/ERK, JNK and p38 multiple mitogen-activated protein kinase pathways. Virology 371, 139-154 (2008).
81. Grossmann C, Ganem D: Effects of NFkB activation on KSHV latency and lytic reactivation are complex and context-dependent. Virology 375, 94-102 (2008).
82. Ye FC, Zhou FC, Xie JP et al.: Kaposi's sarcoma-associated herpesvirus latent gene vFLIP inhibits viral lytic replication through NF-kB-mediated suppression of the AP-1 pathway: a novel mechanism of virus control of latency. J. Virol. 82, 4235-4249 (2008).
83. Sun R, Lin SF, Staskus K et al.: Kinetics of Kaposi's sarcoma-associated herpesvirus gene expression. J. Virol. 73, 2232-2242 (1999). (Pubitemid 29098128)
84. Bottero V, Sharma-Walia N, Kerur N et al.: Kaposi sarcoma-associated herpes virus (KSHV) G protein-coupled receptor (vGPCR) activates the ORF50 lytic switch promoter: a potential positive feedback loop for sustained ORF50 gene expression. Virology 392, 34-51 (2009).
85. Harrison SM, Whitehouse A: Kaposi's sarcoma-associated herpesvirus (KSHV) Rta and cellular HMGB1 proteins synergistically transactivate the KSHV ORF50 promoter. FEBS Lett. 582, 3080-3084 (2008).
86. Li Q, Zhou F, Ye F, Gao SJ: Genetic disruption of KSHV major latent nuclear antigen LANA enhances viral lytic transcriptional program. Virology 379, 234-244 (2008).
87. Pan H, Xie J, Ye F, Gao SJ: Modulation of Kaposi's sarcoma-associated herpesvirus infection and replication by MEK/ERK, JNK, and p38 multiple mitogen-activated protein kinase pathways during primary infection. J. Virol. 80, 5371-5382 (2006).
88. Wang SE, Wu FY, Chen H et al.: Early activation of the Kaposi's sarcoma-associated herpesvirus RTA, RAP, and MTA promoters by the tetradecanoyl phorbol acetate-induced AP1 pathway. J. Virol. 78, 4248-4267 (2004). (Pubitemid 38437229)
89. Wilson SJ, Tsao EH, Webb BL et al.: X box binding protein XBP-1s transactivates the Kaposi's sarcoma-associated herpesvirus (KSHV) ORF50 promoter, linking plasma cell differentiation to KSHV reactivation from latency. J. Virol. 81, 13578-13586 (2007). (Pubitemid 350247851)
90. Dyson OF, Traylen CM, Akula SM: Cell membrane bound KSHV encoded gB promotes virus latency by regulating expression of cellular Egr-1. J. Biol. Chem. 285(48), 37491-37502 (2010).
91. Kojaoghlanian T, Flomenberg P, Horwitz MS: The impact of adenovirus infection on the immunocompromised host. Rev. Med. Virol. 13, 155-171 (2003). (Pubitemid 36566085)
92. Horwitz MS: Adenovirus immunoregulatory genes and their cellular targets. Virology 279, 1-8 (2001). (Pubitemid 34160993)
93. Hayashi S: Latent adenovirus infection in COPD. Chest 121, 183S-187S (2002). (Pubitemid 34497337)
94. Tauber B, Dobner T: Molecular regulation and biological function of adenovirus early genes: the E4 ORFs. Gene 278, 1-23 (2001). (Pubitemid 33055775)
95. Tollefson AE, Scaria A, Hermiston TW, Ryerse JS, Wold LJ, Wold WS: The adenovirus death protein (E3-11.6K) is required at very late stages of infection for efficient cell lysis and release of adenovirus from infected cells. J. Virol. 70, 2296-2306 (1996). (Pubitemid 26087592)
96. Jordan JA, Manley K, Dugan AS, O'Hara BA, Atwood WJ: Transcriptional regulation of BK virus by nuclear factor of activated T cells. J. Virol. 84, 1722-1730 (2010).
97. Gorrill TS, Khalili K: Cooperative interaction of p65 and C/EBPb modulates transcription of BKV early promoter. Virology 335, 1-9 (2005). (Pubitemid 40489047)
98. Manley K, O'Hara BA, Gee GV, Simkevich CP, Sedivy JM, Atwood WJ: NFAT4 is required for JC virus infection of glial cells. J. Virol. 80, 12079-12085 (2006). (Pubitemid 44904358)
99. Gorrill T, Feliciano M, Mukerjee R, Sawaya BE, Khalili K, White MK: Activation of early gene transcription in polyomavirus BK by human immunodeficiency virus type 1 Tat. J. Gen. Virol. 87, 1557-1566 (2006). (Pubitemid 43827208)
100. Duechting A, Tschope C, Kaiser H et al.: Human parvovirus B19 NS1 protein modulates inflammatory signaling by activation of STAT3/PIAS3 in human endothelial cells. J. Virol. 82, 7942-7952 (2008).
101. Lambert PJ, Shahrier AZ, Whitman AG et al.: Targeting the PI3K and MAPK pathways to treat Kaposi's-sarcoma-associated herpes virus infection and pathogenesis. Expert Opin. Ther. Targets 11, 589-599 (2007). (Pubitemid 46744686)
102. Morris TL, Arnold RR, Webster-Cyriaque J: Signaling cascades triggered by bacterial metabolic end products during reactivation of Kaposi's sarcoma-associated herpesvirus. J. Virol. 81, 6032-6042 (2007). (Pubitemid 46847039)
103. Dabaghmanesh N, Matsubara A, Miyake A et al.: Transient inhibition of NF-kB by DHMEQ induces cell death of primary effusion lymphoma without HHV-8 reactivation. Cancer Sci. 100, 737-746 (2009).
104. Yager EJ, Szaba FM, Kummer LW et al.: g-Herpesvirus-induced protection against bacterial infection is transient. Viral Immunol. 22, 67-72 (2009).
105. Barton ES, White DW, Virgin HW: Herpesvirus latency and symbiotic protection from bacterial infection. Viral Immunol. 22, 3-4 (2009).
106. Field HJ, Biswas S, Mohammad IT: Herpesvirus latency and therapy - from a veterinary perspective. Antiviral Res. 71, 127-133 (2006). (Pubitemid 44223781)
107. Barton ES, White DW, Cathelyn JS et al.: Herpesvirus latency confers symbiotic protection from bacterial infection. Nature 447, 326-329 (2007). (Pubitemid 46788830)
108. Boss IW, Renne R: Viral miRNAs: tools for immune evasion. Curr. Opin. Microbiol. 13(4), 540-545 (2010).
109. Gofton TE, Al-Khotani A, O'Farrell B, Ang LC, McLachlan RS: Mefloquine in the treatment of progressive multifocal leukoencephalopathy. J. Neurol. Neurosurg. Psychiatry 82(4), 452-455 (2010).
110. Chakrabarty A, Beutner K: Therapy of other viral infections: herpes to hepatitis. Dermatol. Ther. 17, 465-490 (2004). (Pubitemid 39662750)
111. Lai CM, Lai YK, Rakoczy PE: Adenovirus and adeno-associated virus vectors. DNA Cell Biol. 21, 895-913 (2002). (Pubitemid 36126695)
112. Viscidi RP, Shah KV: Cancer. A skin cancer virus? Science 319, 1049-1050 (2008).
113. Lafferty WE, Downey L, Celum C, Wald A: Herpes simplex virus type 1 as a cause of genital herpes: impact on surveillance and prevention. J. Infect. Dis. 181, 1454-1457 (2000). (Pubitemid 30252554)
114. Chayavichitsilp P, Buckwalter JV, Krakowski AC, Friedlander SF: Herpes simplex. Pediatr. Rev. 30, 119-129 (2009).
115. Azwa A, Barton SE: Aspects of herpes simplex virus: a clinical review. J. Fam. Plann. Reprod. Health Care 35, 237-242 (2009).
116. Steiner I, Kennedy PG, Pachner AR: The neurotropic herpes viruses: herpes simplex and varicella-zoster. Lancet Neurol. 6, 1015-1028 (2007). (Pubitemid 47562323)
117. Lassoued S, Gargouri B, El Feki AE, Attia H, Van Pelt J: Transcription of the Epstein-Barr virus lytic cycle activator BZLF-1 during oxidative stress induction. Biol. Trace Elem. Res. 137(1), 13-22 (2009).
118. Lockey TD, Zhan X, Surman S, Sample CE, Hurwitz JL: Epstein-Barr virus vaccine development: a lytic and latent protein cocktail. Front. Biosci. 13, 5916-5927 (2008).
119. Sinclair E, Tan QX, Sharp M et al.: Protective immunity to cytomegalovirus (CMV) retinitis in AIDS is associated with CMV-specific T cells that express interferon-g and interleukin-2 and have a CD8+ cell early maturational phenotype. J. Infect. Dis. 194, 1537-1546 (2006). (Pubitemid 44851895)
120. Cheng J, Ke Q, Jin Z et al.: Cytomegalovirus infection causes an increase of arterial blood pressure. PLoS Pathog. 5, E1000427 (2009).
121. Yamanishi K, Okuno T, Shiraki K et al.: Identification of human herpesvirus-6 as a causal agent for exanthem subitum. Lancet 1, 1065-1067 (1988).
122. Tanaka K, Kondo T, Torigoe S, Okada S, Mukai T, Yamanishi K: Human herpesvirus 7: another causal agent for roseola (exanthem subitum). J. Pediatr. 125, 1-5 (1994). (Pubitemid 24225167)
123. Hamden KE, Whitman AG, Ford PW, Shelton JG, McCubrey JA, Akula SM: Raf and VEGF: emerging therapeutic targets in Kaposi's sarcoma-associated herpesvirus infection and angiogenesis in hematopoietic and nonhematopoietic tumors. Leukemia 19, 18-26 (2005). (Pubitemid 40090070)
124. Pantry SN, Medveczky PG: Epigenetic regulation of Kaposi's sarcoma-associated herpesvirus replication. Semin. Cancer Biol. 19, 153-157 (2009).
125. Abend JR, Jiang M, Imperiale MJ: BK virus and human cancer: innocent until proven guilty. Semin. Cancer Biol. 19, 252-260 (2009).
126. Compston LI, Sarkobie F, Li C, Candotti D, Opare-Sem O, Allain JP: Multiplex real-time PCR for the detection and quantification of latent and persistent viral genomes in cellular or plasma blood fractions. J. Virol. Methods 151, 47-54 (2008).
127. Michelfelder S, Trepel M: Adeno-associated viral vectors and their redirection to cell-type specific receptors. Adv. Genet. 67, 29-60 (2009).
128. Ljungman P: Treatment of adenovirus infections in the immunocompromised host. Eur. J. Clin. Microbiol. Infect. Dis. 23, 583-588 (2004). (Pubitemid 39222630)
129. Walls T, Shankar AG, Shingadia D: Adenovirus: an increasingly important pathogen in paediatric bone marrow transplant patients. Lancet Infect. Dis. 3, 79-86 (2003). (Pubitemid 36164203)
130. Yang H, Higgins B, Kolinsky K et al.: RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Res. 70, 5518-5527 (2010).
131. Muramoto K, Goto M, Inoue Y et al.: E6201, a Novel Kinase Inhibitor of MEK-1 and MEKK-1: in vivo effects on cutaneous inflammatory responses by topical administration. J. Pharmacol. Exp. Ther. 335(1), 23-31 (2010).
132. Denton CL, Gustafson DL: Pharmacokinetics and pharmacodynamics of AZD6244 (ARRY-142886) in tumor-bearing nude mice. Cancer Chemother. Pharmacol. 67(2), 349-360 (2010).
133. Hsieh HP, Hsu JT: Strategies of development of antiviral agents directed against influenza virus replication. Curr. Pharm. Des. 13, 3531-3542 (2007). (Pubitemid 350238942)
134. LoRusso PM, Krishnamurthi SS, Rinehart JJ et al.: Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers. Clin. Cancer Res. 16, 1924-1937 (2010).
135. Singh D, Smyth L, Borrill Z, Sweeney L, Tal-Singer R: A randomized, placebo-controlled study of the effects of the p38 MAPK inhibitor SB-681323 on blood biomarkers of inflammation in COPD patients. J. Clin. Pharmacol. 50, 94-100 (2010).
136. Damjanov N, Kauffman R S, Spencer- Green GT: Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum. 60, 1232-1241 (2009).
137. Haeusgen W, Boehm R, Zhao Y, Herdegen T, Waetzig V: Specific activities of individual c-Jun N-terminal kinases in the brain. Neuroscience 161, 951-959 (2009).
138. Bogoyevitch MA, Arthur PG: Inhibitors of c-Jun N-terminal kinases: JuNK no more? Biochim. Biophys. Acta 1784, 76-93 (2008).
139. Su Y, Amiri KI, Horton LW et al.: A Phase I trial of bortezomib with temozolomide in patients with advanced melanoma: toxicities, antitumor effects, and modulation of therapeutic targets. Clin. Cancer Res. 16, 348-357 (2010).
140. Chung CH, Aulino J, Muldowney NJ et al.: Nuclear factor-k B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann. Oncol. 21, 864-870 (2010).
141. Sarosiek KA, Cavallin LE, Bhatt S et al.: Efficacy of bortezomib in a direct xenograft model of primary effusion lymphoma. Proc. Natl Acad. Sci. USA 107, 13069-13074 (2010).
142. Bandi P, Garcia ML, Booth CJ, Chisari FV, Robek MD: Bortezomib inhibits hepatitis B virus replication in transgenic mice. Antimicrob. Agents Chemother. 54, 749-756 (2010).
143. Fu DX, Tanhehco Y, Chen J et al.: Bortezomib-induced enzyme-targeted radiation therapy in herpesvirus-associated tumors. Nat. Med. 14, 1118-1122 (2008).
144. Dhillon N, Aggarwal BB, Newman RA et al.: Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin. Cancer Res. 14, 4491-4499 (2008).
145. Rechtman MM, Har-Noy O, Bar-Yishay I et al.: Curcumin inhibits hepatitis B virus via down-regulation of the metabolic coactivator PGC-1a. FEBS Lett. 584, 2485-2490 (2010).